Multiple immune-related targets

The term 'Multiple immune-related targets' is a non-specific designation used to describe a diverse group of proteins involved in the regulation and execution of immune responses. This category encompasses various molecular classes, including cell surface receptors like PD-1 and CTLA-4, secreted cytokines such as TNF and Interleukins, and intracellular signaling molecules like JAK kinases (Janeway's Immunobiology, 9th Edition). These targets are critical in the pathogenesis of numerous conditions, such as cancer, where immune evasion occurs, and autoimmune diseases, where the immune system is overactive (Nature Reviews Drug Discovery, 2018). Because this term does not refer to a single, well-defined molecular entity, it cannot be characterized by a single mechanism of action or a specific set of interacting drugs. In clinical contexts, it often refers to the use of combination therapies or multi-specific agents designed to modulate several pathways simultaneously to improve therapeutic efficacy (Journal of Hematology & Oncology, 2021). Such approaches are increasingly common in oncology to overcome resistance to monotherapy. However, targeting multiple immune pathways also increases the risk of complex safety concerns, such as severe immune-related adverse events (irAEs). Therefore, this entry is classified as incorrect for a specific target database due to its lack of molecular specificity.

Other names

Immune targetsImmunotherapy targetsImmune-related proteins

Not applicable as this is a collective term for various targets with distinct mechanisms.